Glucocorticoids in rheumatoid arthritis

Drugs

Volumn 73, Issue 1, 2013, Pages 31-43

  Caporali, Roberto ^b   Todoerti, Monica ^a   Sakellariou, Garifallia ^a   Montecucco, Carlomaurizio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFLAZACORT; DEXAMETHASONE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG MEGADOSE; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; MENTAL DISEASE; MONOTHERAPY; PERICARDITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; TREATMENT OUTCOME;

EID: 84877044229     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0008-4     Document Type: Review

References (84)

1. Caporali R, Cimmino MA, Montecucco C, et al. Glucocorticoid treatment of polymyalgia rheumatica. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S143-7.
2. Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):1010-4.
3. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560-7.
4. OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. 2012. http://www.cebm.net/index.aspx?o=5653. Accessed 2012.
5. The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, A.C.T.H., and Other Therapeutic Measures in Chronic Rheumatic Diseases. A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis; a report by the joint committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH, and other therapeutic measures in chronic rheumatic diseases. Br Med J. 1954;1(4873):1223-7.
6. The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, A.C.T.H., and Other Therapeutic Measures in Chronic Rheumatic Diseases. A comparison of prednisolone with aspirin on other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis. 1959;18:173-88.
7. The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, A.C.T.H., and Other Therapeutic Measures in Chronic Rheumatic Diseases. A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. A second report by the joint committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH, and other therapeutic measures in chronic rheumatic diseases. Ann Rheum Dis. 1960;19:331-7.
8. Empire Rheumatism Council. Multicentre controlled trial comparing cortisone acetate and acetylsalicylic acid in the long-term treatment of rheumatoid arthritis. Ann Rheum Dis. 1955;14(4):353-70.
9. Criswell LA, Saag KG, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(2):CD001158.
10. Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2004;(3):CD000189.
11. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347-56.
12. Boers M, Verhoeven AC, van der Linden S. Combination therapy in early rheumatoid arthritis: the COBRA study [in Dutch]. Ned Tijdschr Geneeskd. 1997;141(50):2428-32.
13. van Tuyl LH, Boers M, Lems WF, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis. 2010;69(5):807-12.
14. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-90.
15. Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis. 2011;70(2):315-9.
16. Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis. 2004;63(7):797-803.
17. Hansen M, Podenphant J, Florescu A, et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects. Ann Rheum Dis. 1999;58(11):713-8.
18. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52(11):3360-70.
19. Todoerti M, Scire CA, Boffini N, et al. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Acad Sci. 2010;1193:139-45.
20. Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(11):3371-80.
21. Pincus T, Castrejon I, Sokka T. Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: personal experience over 25 years. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S130-8.
22. Harris ED Jr, Emkey RD, Nichols JE, et al. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol. 1983;10(5):713-21.
23. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995;333(3):142-6.
24. Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol. 1998;37(9):930-6.
25. Hafstrom I, Albertsson K, Boonen A, et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis. 2009;68(4):508-13.
26. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136(1):1-12.
27. Jacobs JW, van Everdingen AA, Verstappen SM, et al. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum. 2006;54(5):1422-8.
28. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156(5):329-39.
29. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54(12):3761-73.
30. Bugatti S, Manzo A, Benaglio F, et al. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther. 2012;14(1):R34.
31. Filippucci E, Farina A, Carotti M, et al. Grey scale and power Doppler sonographic changes induced by intra-articular steroid injection treatment. Ann Rheum Dis. 2004;63(6):740-3.
32. Scire CA, Montecucco C, Codullo V, et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology (Oxford). 2009;48(9):1092-7.
33. Teh J, Stevens K, Williamson L, et al. Power Doppler ultrasound of rheumatoid synovitis: quantification of therapeutic response. Br J Radiol. 2003;76(912):875-9.
34. Terslev L, Torp-Pedersen S, Qvistgaard E, et al. Estimation of inflammation by Doppler ultrasound: quantitative changes after intra-articular treatment in rheumatoid arthritis. Ann Rheum Dis. 2003;62(11):1049-53.
35. Montecucco C, Todoerti M, Sakellariou G, et al. Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther. 2012;14(3):R112.
36. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-7.
37. Saleem B, Brown AK, Keen H, et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum. 2009;60(7):1915-22.
38. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573-86.
39. Bijlsma JW, Hoes JN, Van Everdingen AA, et al. Are glucocorticoids DMARDs? Ann N Y Acad Sci. 2006;1069:268-74.
40. van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, et al. The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies. Arthritis Rheum. 2004;51(2):233-8.
41. Govoni M, Caporali R. Predicting and managing the progression of structural damage in rheumatoid arthritis: where do we stand? Clin Exp Rheumatol. 2012;30(4):459-63.
42. Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis. 2012. [Epub ahead of print]
43. Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;(1):CD006356.
44. Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007;56(2):399-408.
45. Straub RH, Cutolo M, Buttgereit F, et al. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med. 2010;267(6):543-60.
46. Kirwan JR, Clarke L, Hunt LP, et al. Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. Ann N Y Acad Sci. 2010;1193:127-33.
47. Vogt M, Derendorf H, Kramer J, et al. Biowaiver monographs for immediate release solid oral dosage forms: prednisone. J Pharm Sci. 2007;96(6):1480-9.
48. Kirkham BW, Panayi GS. Diurnal periodicity of cortisol secretion, immune reactivity and disease activity in rheumatoid arthritis: implications for steroid treatment. Br J Rheumatol. 1989;28(2):154-7.
49. Arvidson NG, Gudbjornsson B, Larsson A, et al. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997;56(1):27-31.
50. Cutolo M, Montecucco CM, Cavagna L, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1438-43.
51. Cutolo M, Seriolo B, Craviotto C, et al. Circadian rhythms in RA. Ann Rheum Dis. 2003;62(7):593-6.
52. Derendorf H, Ruebsamen K, Clarke L, et al. Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. J Clin Pharmacol. 2012. [Epub ahead of print]
53. Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371(9608):205-14.
54. Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1275-80.
55. Alten R, Doring G, Cutolo M, et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol. 2010;37(10):2025-31.
56. Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013;72:204-10.
57. Clarke LL, Jessop DS, Hunt LP, et al. Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int J Clin Rheumatol. 2011;6(2):241-9.
58. Jacobs JW, Geenen R, Evers AW, et al. Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis. Ann Rheum Dis. 2001;60(1):61-4.
59. van der Veen MJ, Bijlsma JW. The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. Clin Rheumatol. 1993;12(4):500-5.
60. Bijlsma JW, Schenk Y, Ramselaar AC, et al. Methylprednisolone pulse therapy in conjunction with azathioprine in rheumatoid arthritis. Clin Rheumatol. 1986;5(4):499-504.
61. Forster PJ, Grindulis KA, Neumann V, et al. High-dose intravenous methylprednisolone in rheumatoid arthritis. Ann Rheum Dis. 1982;41(5):444-6.
62. Hansen TM, Dickmeiss E, Jans H, et al. Combination of methylprednisolone pulse therapy and remission inducing drugs in rheumatoid arthritis. Ann Rheum Dis. 1987;46(4):290-5.
63. Liebling MR, Leib E, McLaughlin K, et al. Pulse methylprednisolone in rheumatoid arthritis: a double-blind cross-over trial. Ann Intern Med. 1981;94(1):21-6.
64. Neumann V, Hopkins R, Dixon J, et al. Combination therapy with pulsed methylprednisolone in rheumatoid arthritis. Ann Rheum Dis. 1985;44(11):747-51.
65. Radia M, Furst DE. Comparison of three pulse methylprednisolone regimens in the treatment of rheumatoid arthritis. J Rheumatol. 1988;15(2):242-6.
66. Smith MD, Ahern MJ, Roberts-Thomson PJ. Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone? Ann Rheum Dis. 1988;47(1):28-33.
67. Smith MD, Bertouch JV, Smith AM, et al. The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. I: clinical effects. J Rheumatol. 1988;15(2):229-32.
68. Williams IA, Baylis EM, Shipley ME. A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease. Lancet. 1982;2(8292):237-40.
69. Choy EH, Kingsley GH, Khoshaba B, et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis. 2005;64(9):1288-93.
70. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263-9.
71. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis. 2008;67(6):815-22.
72. Furtado RN, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. J Rheumatol. 2005;32(9):1691-8.
73. Konai MS, Vilar Furtado RN, Dos Santos MF, et al. Monoarticular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients: a randomized double-blind controlled study. Clin Exp Rheumatol. 2009;27(2):214-21.
74. Caporali R, Conti F, Alivernini S, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol. 2011;29(3 Suppl 66):S7-14.
75. Pincus T, Swearingen CJ, Luta G, et al. Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis. 2009;68(11):1715-20.
76. Tengstrand B, Larsson E, Klareskog L, et al. Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density. Scand J Rheumatol. 2007;36(5):351-8.
77. de Lauretis A, Veeraraghavan S, Renzoni E. Review series. Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease. How does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8(1):53-82.
78. Turesson C, Matteson EL. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol. 2004;16(3):206-11.
79. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76(3):377-84.
80. van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69(11):1913-9.
81. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285-93.
82. Caporali R, Caprioli M, Bobbio-Pallavicini F, et al. DMARDS and infections in rheumatoid arthritis. Autoimmun Rev. 2008;8(2):139-43.
83. Cimmino MA, Moggiana G, Montecucco C, et al. Long term treatment of polymyalgia rheumatica with deflazacort. Ann Rheum Dis. 1994;53(5):331-3.
84. Montecucco C, Caporali R, Caprotti P, et al. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol. 1992;19(12):1895-900.